Lenz Therapeutics (LENZ) announced VIZZ 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through our ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops
- Lenz Therapeutics price target raised to $53 from $44 at BofA
- Lenz Therapeutics price target raised to $56 from $48 at H.C. Wainwright
- Buy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential
- Lenz Therapeutics price target raised to $52 from $49 at Citi